Current ADHD News and Events | Page 24

Current ADHD News and Events, ADHD News Articles.
Sort By: Most Relevant | Most Viewed
Page 24 of 25 | 1000 Results
Capsules effective in treating acute manic and mixed episodes of Bipolar I Disorder
Shire Pharmaceuticals Inc. has announced that University of North Carolina at Chapel Hill researchers studied the efficacy of carbamazepine extended-release capsules (CBZ-ERC, Equetro) in patients with manic or mixed episodes of Bipolar I Disorder over six months. Data from this open label study was presented by UNC researchers last week at the 18th annual US Psychiatric and Mental Health Congress in Las Vegas. (2005-11-16)

Positive study results for methylphenidate transdermal system
Shire announced at the US Psychiatric and Mental Health Congress in Las Vegas, Nevada, that its investigational methylphenidate transdermal system (MTS) demonstrated statistically significant reductions in the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) and was generally well tolerated in patients aged 6 to 12 in two clinical trials. (2005-11-11)

New 'eye movement' test may help treat fetal alcohol syndrome
A simple test that measures eye movement may help to identify children with Fetal Alcohol Spectrum Disorder (FASD) and ultimately lead to improved treatment for the condition, say Queen's University researchers. (2005-11-11)

A good night's sleep can mean a better day at school
When children stay up late, they have more academic and attention problems at school, according to a new study from Brown Medical School to be published in the December issue of the journal SLEEP. The findings indicate that ensuring students get enough sleep is a significant step in helping them maximize learning ability in class as well as minimizing behaviors characteristic of attention-deficit/hyperactivity disorder (ADHD). (2005-11-10)

Shire announces positive two-year study of ADDERALL XR in the treatment of adult ADHD
Adults with attention-deficit/hyperactivity disorder (ADHD) experienced significant long-term ADHD symptom control when treated with once-daily ADDERALL XR® (mixed salts of a single-entity amphetamine product), according to results of a two-year, open-label trial led by Harvard Medical School investigators at Massachusetts General Hospital, presented today at the US Psychiatric & Mental Health Congress. (2005-11-09)

ADDERALL XR significantly improves driving performance, attention in young adults with ADHD
ADDERALL XR significantly improved driving performance, cognitive function and attention in young adults with attention-deficit/hyperactivity disorder (ADHD) in a driving study presented at the 18th Annual US Psychiatric & Mental Health Congress. Adolescent and adult patients often fail to appreciate the effect that ADHD symptoms such as inattention have on daily activities such as driving. (2005-11-08)

Children of bipolar parents score higher on creativity test, Stanford study finds
Researchers at the Stanford University School of Medicine have shown for the first time that a sample of children who either have or are at high risk for bipolar disorder score higher on a creativity index than healthy children. The findings add to existing evidence that a link exists between mood disorders and creativity. (2005-11-08)

Antisocial behavior in children associated with gene variant and environmental risk factors
For children with attention deficit hyperactivity disorder (ADHD), possessing a variant of a gene involved in brain signaling may predict antisocial behavior and increase susceptibility to the effects of lower birth weight, according to a study in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals. (2005-11-07)

Medication shows promise in the treatment of hyperactivity associated with autism-related disorders
Medication commonly used to treat attention-deficit hyperactivity disorder (ADHD) may be effective for treatment of hyperactivity symptoms in children with autism and related pervasive developmental disorders, according to a study in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals. (2005-11-07)

Positive study results for methylphenidate transdermal system
Shire announced at a major medical meeting in Toronto, Canada, that its investigational methylphenidate transdermal system (MTS) demonstrated statistically significant reductions in the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) and was generally well tolerated in patients aged 6 to 12 in two clinical trials. (2005-10-24)

Autism problems explained in new research
New research from Melbourne's Howard Florey Institute helps to explain why children with autism spectrum disorders (autism) have problem-solving difficulties. Using functional magnetic resonance imaging technology (fMRI) the Florey scientists have shown that children with autism have less activation in the deep parts of the brain responsible for executive function (attention, reasoning and problem solving). (2005-10-24)

Extended release stimulant effective for long-term ADHD treatment
A new study has found that an all-day, extended-release stimulant for treating attention-deficit hyperactivity disorder (ADHD) remains effective for up to two years without significant side effects. (2005-10-03)

Nation's experts to answer questions about attention-deficit/hyperactivity disorder
To help patients, families and caregivers better understand ADHD, Shire Pharmaceuticals Inc. will host the seventh annual ADHD Experts on Call, September 22, from 8 a.m. to midnight EDT. The toll-free hotline, 1-888-ASK-ADHD, provides access to English- and Spanish-speaking ADHD experts including physicians, school nurses, and educators. Celebrity carpenter Ty Pennington, who has ADHD, will talk about his experience. A confidential, one-on-one online forum will be available at (2005-09-14)

Key research findings show family therapy is an effective treatment tool for children
Family-based treatments are effective for substance abuse and conduct disorders in children and adolescents, according to a new, ten-year research review. The treatment also helps reduce the behavior problems associated with attention deficit hyperactivity disorder (ADHD) and shows promise in treating depression and anxiety. (2005-08-11)

Polypharmacy in children on the rise in the US
Pediatric polypharmacy, the practice of prescribing two or more medications for psychiatric symptoms in children, is on the rise in the United States, raising concern about unknown side effects, according to a new study appearing in the August issue of the journal Psychiatry 2005 (2005-08-01)

FDA expands indication for ADDERALL XR® (CII) confirming safety and efficacy in adolescents
Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the US Food and Drug Administration (FDA) has approved ADDERALL XR® (mixed salts of a single-entity amphetamine product) as a once-daily treatment for adolescents aged 13 to 17 with attention deficit hyperactivity disorder (ADHD). (2005-07-22)

Leading researchers to discuss latest treatments for mental illness in children and adolescents
Renowned experts in the fields of childhood and adolescent mental-health problems will gather next month to discuss new and effective treatments for a wide-range of mental illnesses affecting children and teens at the fourth Biennial Niagara Conference on Evidence Based Treatments for Childhood and Adolescent Health Problems. (2005-06-24)

New finding in studying dopamine transporter
Yale researchers observed an altered availability of the dopamine transporter in healthy persons with a genetic variation linked to substance abuse and attention deficit hyperactivity disorder. (2005-06-06)

New data show the efficacy of EQUETRO in patients with Bipolar I Disorder
Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that EQUETROTM (carbamazepine extended-release capsules) are effective in significantly reducing the manic symptoms in patients with Bipolar I Disorder previously taking valproate or lithium, according to a pooled analysis of two phase 3 trials, one of two posters about carbamazepine extended-release capsules presented today at a major medical meeting in Atlanta, Ga. (2005-05-25)

$77 billion in lost income is attributed to ADHD annually in the United States
U.S. household income losses due to attention-deficit/hyperactivity disorder (ADHD) total nearly $77 billion each year, according to a new analysis of the national large-scale survey, (2005-05-23)

NYU Child Study Center presents third Annual Adam Katz Memorial Lecture series
The New York University Child Study Center is pleased to announce the Third Annual Adam Katz Lecture Series, which includes two lectures on Thursday, May 19 and Friday, May 20, 2005. The series focuses on learning difficulties and Attention-Deficit/Hyperactivity Disorder (ADHD). The Adam Katz Memorial Series was created in 2003 as a tribute to the life of Adam Katz, son of Child Study Center board member Howard Katz, who suffered from ADHD and learning difficulties throughout his life. (2005-05-17)

Study finds ADHD improves with sensory intervention
Preliminary findings from a study of children with attention deficit hyperactivity disorder (ADHD) show that sensory intervention -- for example, deep pressure and strenuous exercise -- can significantly improve problem behaviors such as restlessness, impulsivity and hyperactivity. (2005-05-16)

Medication combined with behavior therapy works best for ADHD children, study finds
A new study of treatments for children with attention deficit hyperactivity disorder (ADHD) has found that combining behavior modification therapy with medication is the most effective way to improve the behavior of many ADHD children. (2005-05-05)

Nation's leading researchers, scientists reveal findings at occupational therapy conference
Thousands of occupational therapy educators, practitioners, scientists and students from across the country will gather from May 12 to 15 at the 85th Annual Conference & Expo of the American Occupational Therapy Association (AOTA). The Conference & Expo will feature almost 250 education sessions and keynote and plenary presentations. Panel discussions and workshops will bring together leading experts to explore key issues for advancing the quality and availability of occupational therapy and research. (2005-05-02)

Does the college experience damage your brain?
Is college grade-point average the best marker of future job success? Not in today's stressed-out world, says brain researcher Dr. Fred Travis. (2005-03-15)

Many company benefits can help parents meet needs of children with ADHD
Health care and related services for children with attention-deficit hyperactivity disorder (ADHD) usually depend on the medical insurance and other programs offered by their parents' employers. A new study from researchers at MassGeneral Hospital for Children finds that many of the benefits offered by employers could address the needs of parents of children with ADHD, although they may be underutilized. (2005-02-28)

Women should be advised not to drink alcohol in pregnancy
Expectant mothers should be advised not to drink alcohol, as this may pose health risks to the foetus, argues an editorial in this week's BMJ. (2005-02-18)

Study shows strengths, gaps in quality of care for kids in California's public mental health clinics
A UCLA-led study of children's patient records at California's public mental health clinics identifies strengths and gaps in quality of care. For example, nearly three-quarters of patient records of children receiving psychoactive medication did not document adequate safety monitoring through vital signs or laboratory studies. The study examines safety and appropriateness of care for attention deficit hyperactivity disorder (ADHD), conduct disorder and major depression in the public clinics. It is the first statewide study on quality of care for children. (2005-01-20)

Drug to treat ADHD has similar effect on children with reading disorders
The drug methylphenidate (brand name Ritalin) increased activity in brains of children with attention-deficit/hyperactivity disorder (ADHD) as well as those with a reading disorder, researchers at Yale report in the American Journal of Psychiatry. (2004-12-13)

New studies on Ritalin and Alzheimer's Disease highlight ACNP Annual Meeting
Hundreds of new studies on brain and behavior from the world's most renowned scientists will headline the American College of Neuropsychopharmacology's 2004 Annual Meeting. Presentations include new studies on the effects of early Ritalin exposure on normal brains and the top smells than can predict Alzheimer's Disease. (2004-12-12)

New study shows early ritalin may cause long-term effects on the brain
A new study conducted in rats by the National Institutes of Health (NIH) and McLean Hospital/Harvard Medical School suggests that the misdiagnosis of attention-deficit hyperactivity disorder (ADHD) combined with prescription drug use in children may lead to a higher risk of developing depressive symptoms in adulthood. (2004-12-12)

Novel imaging technique shows abnormal brain anatomy in children with ADHD
Children with attention deficit hyperactivity disorder (ADHD) display anatomical brain abnormalities beyond chemical imbalance, according to research presented at the annual meeting of the Radiological Society of North America (RSNA). Stimulant medications prescribed to balance brain chemistry appear to normalize some of these brain irregularities, a second study reported. (2004-11-29)

Data suggest ADDERALL XR ® significantly improved simulated driving in young adults with ADHD
The Washington Neuropsychological Institute today announced that preliminary data suggested that ADDERALL XR (R) significantly improved simulated driving performance in young adults aged 19 to 25 with attention-deficit/hyperactivity disorder (ADHD) for up to 12 hours after taking the medication, as compared with placebo. In addition, ADDERALL XR significantly improved ADHD symptom control. (2004-11-18)

Top 10 toys for children with ADHD
The top 10 toys for children with attention-deficit/hyperactivity disorder (ADHD), along with selection criteria designed to help guide parents, were announced by Shire and the Oppenheim Toy Portfolio. The list was developed based on the specific needs of children with ADHD, including the need to better focus attention, to gain self-confidence and to learn to socialize and interact appropriately with other children. (2004-11-16)

Reductions in blood oxygen levels in newborns could contribute to ADHD development
A repetitive drop in blood oxygen levels in newborn rats, similar to that caused by apnea (brief pauses in breathing) in some human infants, is followed by a long-lasting reduction in the release of the brain neurotransmitter dopamine, according to an Emory University research study. Because dopamine promotes attention, learning, memory and a variety of higher cognitive functions, the researchers believe repetitive apnea during neonatal development may be one factor leading to the development of attention deficit hyperactivity disorder (ADHD). (2004-10-24)

Long-term study demonstrated ADDERALL XR® is an effective option to treat adolescents with ADHA
Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced today that ADDERALL XR® (an extended release, mixed salts amphetamine product) is effective and generally well-tolerated for adolescents with attention-deficit/hyperactivity disorder (ADHD). (2004-10-20)

Study published in Mayo Clinic Proceedings finds risk of ADHD greater in boys
Boys, in general, and children born to parents who have low education levels, in particular, are at an increased risk for developing attention-deficit/hyperactivity disorder (ADHD) compared to girls and children born to parents with high levels of education, according to a study of 5,701 children in Olmsted County, Minn. For the purpose of this study, low levels of education were defined as 12 years or less and high levels of education were defined as 15 or more years. (2004-09-14)

New analysis cites economic impact of ADHD
A new analysis of a large-scale survey released today estimates yearly household income losses due to attention deficit hyperactivity disorder (ADHD) within the U.S. at $77 billion, according to Harvard researcher, Joseph Biederman, M.D., co-author of the study, speaking at an American Medical Association media briefing on ADHD in New York City. (2004-09-09)

Pediatricians treating more children with behavioral health disorders, study shows
Pediatricians are diagnosing and treating a growing number of children with behavioral health problems. However, they do not always feel comfortable or sufficiently trained to fill this new role, according to a study from Wake Forest University Baptist Medical Center. (2004-09-07)

Children with ADHD benefit from time outdoors enjoying nature
Kids with attention deficit hyperactive disorder (ADHD) should spend some quality after-school hours and weekend time outdoors enjoying nature, say researchers at the University of Illinois at Urbana-Champaign. The payoff for this (2004-08-27)

Page 24 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.